Cognetivity Neurosciences Valuation

Is CGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CGN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CGN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CGN?

Key metric: As CGN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CGN. This is calculated by dividing CGN's market cap by their current revenue.
What is CGN's PS Ratio?
PS Ratio	9.5x
Sales	CA$98.97k
Market Cap	CA$935.57k

CGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	107.1x
Enterprise Value/EBITDA	-2.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CGN's PS Ratio compare to its peers?

The above table shows the PS ratio for CGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7x
SCYB Scryb	3.1x	n/a	CA$4.8m
EVMT Evome Medical Technologies	0.2x	n/a	CA$10.7m
ASEP ASEP Medical Holdings	22.7x	n/a	CA$4.6m
SQD.H SQI Diagnostics	2x	n/a	CA$6.1m
CGN Cognetivity Neurosciences	9.5x	n/a	CA$935.6k

Price-To-Sales vs Peers: CGN is expensive based on its Price-To-Sales Ratio (9.5x) compared to the peer average (7.6x).

Price to Sales Ratio vs Industry

How does CGN's PS Ratio compare vs other companies in the CA Medical Equipment Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
HTL Hamilton Thorne	3.2x	9.1%	US$246.64m
NSCI Nanalysis Scientific	1x	n/a	US$29.94m
ASG Aurora Spine	1.5x	n/a	US$24.93m
EVMT Evome Medical Technologies	0.2x	n/a	US$7.69m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: CGN is expensive based on its Price-To-Sales Ratio (9.5x) compared to the North American Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is CGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CGN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	9.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CGN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

NeuPath Health

CA$9.6m

Provides chronic pain management services in Canada.

NPTH

CA$0.16

-5.9%

Hamilton Thorne

CA$344.7m

Develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets.

HTL

CA$2.24

79.2%

Medical Facilities

CA$362.7m

Through its subsidiaries, owns and operates specialty hospitals and ambulatory surgery center in the United States.

CA$15.87

83.9%